Polypid Ltd (PYPD) gains 1.85% for July 21

Equities Staff  |

Polypid Ltd (NASDAQ: PYPD) shares gained 1.85%, or $0.14 per share, to close Wednesday at $7.69. After opening the day at $7.65, shares of Polypid fluctuated between $7.78 and $7.55. 21,702 shares traded hands a decrease from their 30 day average of 32,759. Wednesday's activity brought Polypid’s market cap to $142,224,543.

About Polypid Ltd

PolyPid Ltd. is a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).

Visit Polypid Ltd’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Polypid Ltd and to follow the company’s latest updates, you can visit the company’s profile page here: Polypid Ltd’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content